Alnylam Pharmaceuticals, Inc. with ticker code (ALNY) have now 23 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 405 and 141 with the average target price sitting at $246.47. Given that the stocks previous close was at $185.79 this indicates there is a potential upside of 32.7%. It’s also worth noting that there is a 50 day moving average of $194.41 and the 200 moving average now moves to $206.42. The market cap for the company is 22.58B. The stock price is currently at: 181.35 USD
The potential market cap would be $29,958,449,253 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 10.01 and a -15.34% return on assets.
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.
